MASI Quote, Financials, Valuation and Earnings

Insulet Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 12.4%. Masimo Corp.'s return on equity of -19.18% beat Insulet Corp.'s return on equity of 18.92%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 27.67%. On the other hand Insulet Corp. has an analysts' consensus of $373.84 which suggests that it could grow by 33.51%. Given that Insulet Corp. has higher upside potential than Masimo Corp., analysts believe Insulet Corp. is more attractive than Masimo Corp..

Masimo Corp. has a beta of 1.263, which suggesting that the stock is 26.337% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.400, suggesting its more volatile than the S&P 500 by 39.975%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Masimo Corp.'s net income of $53.7M is lower than Insulet Corp.'s net income of $87.6M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Insulet Corp.'s PE ratio is 81.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.55x versus 8.04x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 26.1%. Masimo Corp.'s return on equity of -19.18% beat ResMed, Inc.'s return on equity of 25.6%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 27.67%. On the other hand ResMed, Inc. has an analysts' consensus of $292.33 which suggests that it could grow by 14.48%. Given that Masimo Corp. has higher upside potential than ResMed, Inc., analysts believe Masimo Corp. is more attractive than ResMed, Inc..

Masimo Corp. has a beta of 1.263, which suggesting that the stock is 26.337% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.416%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.89% to investors and pays a quarterly dividend of $0.60 per share. Masimo Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. Masimo Corp.'s net income of $53.7M is lower than ResMed, Inc.'s net income of $348.5M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while ResMed, Inc.'s PE ratio is 26.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.55x versus 7.15x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

UFP Technologies, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 10.6%. Masimo Corp.'s return on equity of -19.18% beat UFP Technologies, Inc.'s return on equity of 18.42%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 27.67%. On the other hand UFP Technologies, Inc. has an analysts' consensus of $329.50 which suggests that it could grow by 23.57%. Given that Masimo Corp. has higher upside potential than UFP Technologies, Inc., analysts believe Masimo Corp. is more attractive than UFP Technologies, Inc..

Masimo Corp. has a beta of 1.263, which suggesting that the stock is 26.337% more volatile than S&P 500. In comparison UFP Technologies, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.859%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. UFP Technologies, Inc. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are larger than UFP Technologies, Inc. quarterly revenues of $154.6M. Masimo Corp.'s net income of $53.7M is higher than UFP Technologies, Inc.'s net income of $16.4M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while UFP Technologies, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.55x versus 3.47x for UFP Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 17.41%. Masimo Corp.'s return on equity of -19.18% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Masimo Corp. has a consensus price target of $183.75, signalling upside risk potential of 27.67%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 39.53%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Masimo Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Masimo Corp..

Masimo Corp. has a beta of 1.263, which suggesting that the stock is 26.337% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.34% to investors and pays a quarterly dividend of $0.22 per share. Masimo Corp. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Masimo Corp.'s net income of $53.7M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while West Pharmaceutical Services, Inc.'s PE ratio is 36.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.55x versus 5.98x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.